Cytogen - Worst Pharma Stocks of 2007

Company: Cytogen
Starting stock price: $2.55
Ending stock price: $0.53
Percent Change: -79.22%

Details: Cytogen has four marketed products and is developing CYT-500, a third-generation radiolabeled antibody to treat prostate cancer. The company's stock declined steadily through the second half of 2007. In November Cytogen told analysts that the company was hiring an investment firm to examine its "strategic alternatives." Those alternatives--designed to satisfy the never-ending pursuit of maximizing shareholder value--ranged from licensing new products to selling the company or merging.

More News:
Cytogen execs hit the road. Report
Cytogen to raise $10.1M. Report

Cytogen - Worst Pharma Stocks of 2007
Read more on

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.